Stock of the Day - November 10, 2023

STAAR Surgical (STAA)

$21.27

-$0.99 (-4.4%)

Market Cap: $1.12B

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.

The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Today's Trend

STAAR Surgical Company (NASDAQ: STAA) moved higher after Stifel Nicolaus upgraded the stock, citing stronger growth potential—particularly in China—and meaningful upside to its revised price target.

Stifel upgraded STAAR Surgical from “Hold” to “Buy” and raised its price target to $31 from $28. The new target implies approximately 37% upside from the referenced $22.61 share price, providing a significant bullish catalyst. STAAR Surgical Shares Rise After Stifel Upgrade
The analyst highlighted STAAR Surgical’s potential for topline growth in China, where increasing adoption of the company’s implantable collamer lenses could support revenue expansion and improve investor expectations. STAAR Surgical jumps on Stifel upgrade citing China growth potential
The upgrade reversed a previously cautious analyst stance and helped fuel a broad bullish reaction, with coverage emphasizing potential for “meaningful” upside relative to current Street expectations. Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Overall, the news is favorable for STAA because it raises confidence in the company’s international growth opportunity and establishes a higher valuation benchmark. However, the stock remains dependent on execution in China and broader demand for its specialty ophthalmic products.

← Previous Stock of the Day Next Stock of the Day →

STAAR Surgical (STAA)

About STAAR Surgical

Today's Trend

Recent News